Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: A two-phase, crossover study in healthy subjects

International Journal of Clinical Pharmacology and Therapeutics

Volumn 48, Issue 1, 2010, Pages 46-58

  Karim, A ^a   Covington, P ^b   Christopher, R ^c   Davenport, M ^b   Fleck, P ^a   Li, X ^b   Wann, E ^a,d   Mekki, Q ^a  

^a TAKEDA PHARMACEUTICALS   (United States)

^b Pharmaceutical Product Development   (United States)

^c Takeda San Diego Inc   (United States)

^d ABBOTT LABORATORIES   (United States)

Author keywords

Alogliptin; Dipeptidyl peptidase 4 inhibitor; Metformin; Pharmacokinetics; Type 2 diabetes mellitus

Indexed keywords

ALOGLIPTIN; CIMETIDINE; METFORMIN;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DISTRIBUTION VOLUME; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG URINE LEVEL; DYSPEPSIA; FEMALE; FOOD DRUG INTERACTION; GASTROINTESTINAL DISEASE; HUMAN; HUMAN EXPERIMENT; KIDNEY CLEARANCE; LIPID DIET; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NAUSEA; NEUROLOGIC DISEASE; NORMAL HUMAN; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; URINALYSIS; VOMITING;

EID: 73649128872     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP48046     Document Type: Article

References (28)

1. Drucker DJ. The role of gut hormones in glucose homeostasis. J Clin Invest. 2007; 117: 24-32.
2. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in Type 2 diabetes. Lancet. 2006; 368: 1696-1705.
3. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidylpeptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36 amide), and peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem. 1993; 214: 829-835.
4. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept. 1999; 85: 9-24.
5. Mentlein R. Therapeutic assessment of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase IV inhibitors as potential antidabetic drugs. Expert Opin Investig Drugs. 2005; 14: 57-64.
6. Herman GA, Stein PP, Thornberry NA,Wagner JA. Dipeptidyl peptidase-4 inhibitors for the treatment of Type 2 diabetes: focus on sitagliptin. Clin Pharmacol Ther. 2007; 81: 761-767.
7. Kleppinger E, Helms K. The role of vildagliptin in the management of Type 2 diabetes mellitus. Ann Pharmacother. 2007; 41: 824-832.
8. Feng J, Zhang Z, Wallace M et al. The discovery of alogliptin (SYR-322): a potent, selective, bioavailable and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem. 2007; 50: 2297-2300.
9. Lee B, Shi L, Kassel DB et al. Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys. Eur J Pharmacol. 2008; 589: 306-314.
10. Moritoh Y, Takeuchi K, Asakawa T, Kataoka O, Odaka H. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice. Eur J Pharmacol. 2008; 588: 325-332.
11. Christopher R, Covington P Davenport M et al. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. Clin Ther. 2008; 30: 499-512.
12. Covington P, Christopher R, Davenport M et al. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase 4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled multiple-dose study in adult patients with Type 2 diabetes. Clin Ther. 2008; 30: 513-527.
13. Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 1996; 30: 359-371.
14. Bodemar G, Norlander B, Walan A. Pharmacokinetics of cimetidine after single doses and during continuous treatment. Clin Pharmacokinet. 1981; 6: 306-315.
15. Rocha J-F, Vaz-da-Silva M, Almeida et al. Effect of eslicarbazepine acetate on the pharmacokinetics of metformin in healthy subjects. Int J Clin Pharmacol Ther. 2009; 47: 255-261.
16. Rowland M, Tozer T. Clinical Pharmacokinetics: Concepts and Applications, 3rd ed. Baltimore: Williams & Wilkins; 1995.
17. Glucophage/Glucophage XR package insert (2008) Bristol-Myers Squibb Co., Princeton, NJ, USA.
18. Nauck M, Ellis G, Fleck P, Wilson C, Mekki Q. Efficacy and safety of alogliptin added to metformin therapy in patients with Type 2 diabetes. Presented at the 68th Annual Scientific Sessions of the American Diabetes Association. June 6-10, 2008, San Francisco, California. Abstract number 477-P.
19. Kimura N, Masuda S, Tanihara Y et al. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet. 2005; 20: 379-386.
20. Chu XY, Bleasby K, Yabut J et al. Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. J Pharmacol Exp Ther. 2007; 321: 673-683.
21. Herman GA, Bergman A, Yi B, Kipnes M. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with Type 2 diabetes. Curr Med Res Opin. 2006; 22: 1939-1937.
22. Karim A, Fleck P, Harris S, Weiss M, Zhang W, Mekki Q. Lack of pharmacokinetic interaction between multiple doses of the dipeptidyl peptidase-4 inhibitor alogliptin and digoxin in healthy subjects. Clin Pharmacol Ther. 2008; 83(Suppl): 12. Abstract.
23. Karim A, Chiselko P, Fleck P, Harris S, Munsaka M, Mekki Q. Lack of effect of cyclosporine on the single-dose pharmacokinetics of alogliptin benzoate, a novel dipeptidyl peptidase-4 inhibitor, in healthy male subjects. Clin Pharmacol Ther. 2008; 83(Suppl): 13. Abstract.
24. Somogyi A, Stockley C, Keal J, Rolan P, Bochner F. Reduction of metformin renal tubular secretion by cimetidine in man. Br J Clin Pharmacol. 1987; 23: 545-551.
25. 2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005; 315: 337-345.
26. Karyekar CS, Eddington ND, Briglia A, Gubbins PO, Dowling TC. Renal interaction between itraconazole and cimetidine. J Clin Pharmacol. 2004; 44: 919-927.
27. Bacracheva N, Tyutyulkova N, Drenska A et al. Effect of cimetidine on the pharmacokinetics of the metabolites of metamizol. Int J Clin Pharmacol Ther. 1997; 35: 275-281.
28. Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996; 334: 574-579.